Evaluation of the changes in exposure to thiol compounds in chronic kidney disease patients using the PBPK model

References

• Algaier I, Jakubowski JA, Asai F, von Kügelgen I. (2008). Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 6:1908–14.
   PubMed Web of Science ®Google Scholar
• Baillie TA. (2016). Targeted covalent inhibitors for drug design. Angew Chem Int Ed Engl 55:13408–21.
   PubMed Web of Science ®Google Scholar
• Bauer RA. (2015). Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today 20:1061–73.
   PubMed Web of Science ®Google Scholar
• Campbell CL, Berger PB, Nuttall GA, et al. (2005). Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. Am Heart J 150:796–9.
   PubMed Web of Science ®Google Scholar
• Carlsson SM, Denneberg T, Emanuelsson BM, et al. (1990). Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. Eur J Clin Pharmacol 38:499–503.
   PubMed Web of Science ®Google Scholar
• Carlsson SM, Denneberg T, Emanuelsson BM, et al. (1994a). Pharmacokinetics of 2-mercaptopropionylglycine (Tiopronin) in patients with impaired renal function. Drug Investig 7:101–12.
   Google Scholar
• Carlsson SM, Denneberg T, Emanuelsson BM, et al. (1994b). Steady-state pharmacokinetics of 2-mercaptopropionylglycine (Tiopronin) in healthy volunteers and patients with cystinuria. Drug Investig 7:41–51.
   Google Scholar
• De Nicola L, Zoccali C. (2016). Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant 31:331–5.
   PubMed Web of Science ®Google Scholar
• Derks M, Kawamura H, Abt M, et al. (2011). Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers. Clin Ther 33:754–65.
   PubMed Web of Science ®Google Scholar
• Dreisbach AW. (2009). The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther 86:553–6.
   PubMed Web of Science ®Google Scholar
• Drummer OH, Miach P, Jarrott B. (1983). S-methylation of captopril. Demonstration of captopril thiol methyltransferase activity in human erythrocytes and enzyme distribution in rat tissues. Biochem Pharmacol 32:1557–62.
   PubMed Web of Science ®Google Scholar
• Duchin KL, Singhvi SM, Willard DA, et al. (1982). Captopril kinetics. Clin Pharmacol Ther 31:452–8.
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, et al. (2007). The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35:1096–104.
   PubMed Web of Science ®Google Scholar
• Goldsborough AS, Handley MD, Dulcey AE, et al. (2011). Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. J Med Chem 54:4987–97.
   PubMed Web of Science ®Google Scholar
• Gross G, Tardio J, Kuhlmann O. (2012). Solubility and stability of dalcetrapib in vehicles and biological media. Int J Pharm 437:103–9.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Kazui M, Ikenaga H, et al. (2011). The intestine as an important contributor to prasugrel active metabolite formation in vivo. Drug Metab Dispos 39:565–70.
   PubMed Web of Science ®Google Scholar
• Hill NR, Fatoba ST, Oke JL, et al. (2016). Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One 11:e0158765.
   PubMed Web of Science ®Google Scholar
• Hsueh CH, Hsu V, Zhao P, et al. (2018). PBPK modeling of the effect of reduced kidney function on the pharmacokinetics of drugs excreted renally by organic anion transporters. Clin Pharmacol Ther 103:485–92.
   PubMed Web of Science ®Google Scholar
• Husser C, Pähler A, Seymour M, et al. (2018). Profiling of dalcetrapib metabolites in human plasma by accelerator mass spectrometry and investigation of the free phenothiol by derivatisation with methylacrylate. J Pharm Biomed Anal 152:143–54.
   PubMed Web of Science ®Google Scholar
• Kazui M, Hagihara K, Izumi T, et al. (2014). Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. Drug Metab Dispos 42:1138–45.
   PubMed Web of Science ®Google Scholar
• Leblond FA, Petrucci M, Dubé P, et al. (2002). Downregulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol 13:1579–85.
   PubMed Web of Science ®Google Scholar
• Lonsdale R, Ward RA. (2018). Structure-based design of targeted covalent inhibitors. Chem Soc Rev 47:3816–30.
   PubMed Web of Science ®Google Scholar
• Naud J, Michaud J, Boisvert C, et al. (2007). Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 320:978–85.
   PubMed Web of Science ®Google Scholar
• Nolin TD, Naud J, Leblond FA, Pichette V. (2008). Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898–903.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K, et al. (2000). A cholesteryl ester transfer protein inhibitor attenuate atherosclerosis in rabbits. Nature 406:203–7.
   PubMed Web of Science ®Google Scholar
• Onoyama K, Hirakata H, Iseki K, et al. (1981). Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. Hypertension 3:456–9.
   PubMed Web of Science ®Google Scholar
• Phelan M, Anzures-Cabrera J, Carlile DJ, et al. (2013). Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol? Clin Pharmacokinet 52:255–65.
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. (2002). Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129–56.
   PubMed Web of Science ®Google Scholar
• Rehmel JLF, Eckstein JA, Farid NA, et al. (2006). Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:600–7.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Leahy D, Rowland M. (2005). Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259–76.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. (2006). Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–57.
   PubMed Web of Science ®Google Scholar
• Sayama H, Komura H, Kogayu M, Iwaki M. (2013). Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics. J Pharm Sci 102:4193–204.
   PubMed Web of Science ®Google Scholar
• Sayama H, Takubo H, Komura H, et al. (2014). Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients. AAPS J 16:1018–28.
   PubMed Web of Science ®Google Scholar
• Small DS, Wrishko RE, Ernest CS, et al. (2009). Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther 34:585–94.
   PubMed Web of Science ®Google Scholar
• Takubo H, Ishikawa T, Kuhlmann O, et al. (2014). Pharmacokinetics and disposition of dalcetrapib in rats and monkeys. Xenobiotica 44:1117–26.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). (2010). Guidance for industry pharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing and labeling. https://www.fda.gov/media/78573/download
   Google Scholar
• Williams ET, Jones KO, Ponsler GD, et al. (2008). The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 36:1227–32.
   PubMed Web of Science ®Google Scholar
• Zhao P, Vieira ML, Grillo JA, et al. (2012). Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol 52:91S–108S.
   PubMed Web of Science ®Google Scholar